These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 3678329)

  • 21. Mathematical modelling of tumour response in primary breast cancer.
    Cameron DA; Gregory WM; Bowman A; Leonard RC
    Br J Cancer; 1996 Jun; 73(11):1409-16. PubMed ID: 8645588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Model for tumour growth with treatment by continuous and pulsed chemotherapy.
    Borges FS; Iarosz KC; Ren HP; Batista AM; Baptista MS; Viana RL; Lopes SR; Grebogi C
    Biosystems; 2014 Feb; 116():43-8. PubMed ID: 24333154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal drug regimens in cancer chemotherapy for single drugs that block progression through the cell cycle.
    Murray JM
    Math Biosci; 1994 Oct; 123(2):183-213. PubMed ID: 7827419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of cellular resistance in tumours to cytotoxic chemotherapy and radiotherapy.
    Pomeroy M; Moriarty M
    Cytotechnology; 1993; 12(1-3):385-91. PubMed ID: 7764459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.
    Boldrini JL; Costa MI
    IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy may be delivered based on an integrated view of tumour dynamics.
    Ribba B; You B; Tod M; Girard P; Tranchand B; Trillet-Lenoir V; Freyer G
    IET Syst Biol; 2009 May; 3(3):180-90. PubMed ID: 19449978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance.
    Hamis S; Nithiarasu P; Powathil GG
    J Theor Biol; 2018 Oct; 454():253-267. PubMed ID: 29909142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal chemical control of populations developing drug resistance.
    Costa MI; Boldrini JL; Bassanezi RC
    IMA J Math Appl Med Biol; 1992; 9(3):215-26. PubMed ID: 1295929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mathematical models in high-dose chemotherapy.
    Souhami RL; Gregory WM; Birkhead BG
    Antibiot Chemother (1971); 1988; 41():21-8. PubMed ID: 3245689
    [No Abstract]   [Full Text] [Related]  

  • 30. [Exponential growth status of the cell number. I. The independence of the portion of proliferating cells found in different phases of the mitotic cycle from the variability in phase durations].
    Gushchin VA
    Tsitologiia; 1981 Dec; 23(12):1428-36. PubMed ID: 7330982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer chemotherapy.
    Secchi GC
    Ann Ital Med Int; 1990; 5(3 Pt 3):288-95. PubMed ID: 2081089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. General applications of optimal control theory in cancer chemotherapy.
    Swan GW
    IMA J Math Appl Med Biol; 1988; 5(4):303-16. PubMed ID: 3241099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mathematical model for human myeloma relating growth kinetics and drug resistance.
    Hokanson JA; Brown BW; Thompson JR; Jansson B; Drewinko B
    Cell Tissue Kinet; 1986 Jan; 19(1):1-10. PubMed ID: 3955625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A stochastic model of the acquisition of drug resistance during antineoplastic chemotherapy.
    Abundo M; Rossi C; Benassi M; Gentile FP; Mauro F
    Health Phys; 1989; 57 Suppl 1():349-54. PubMed ID: 2606692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling and optimization of combined cytostatic and cytotoxic cancer chemotherapy.
    Villasana M; Ochoa G; Aguilar S
    Artif Intell Med; 2010 Nov; 50(3):163-73. PubMed ID: 20620035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of mathematical modeling in protocol formulation in cancer chemotherapy.
    Coldman AJ; Goldie JH
    Cancer Treat Rep; 1985 Oct; 69(10):1041-8. PubMed ID: 2412691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A mathematical model of cancer chemotherapy with an optimal selection of parameters.
    Martin RB; Fisher ME; Minchin RF; Teo KL
    Math Biosci; 1990 May; 99(2):205-30. PubMed ID: 2134520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 1.
    Gurney H; Dodwell D; Thatcher N; Tattersall MH
    Ann Oncol; 1993 Jan; 4(1):23-34. PubMed ID: 8435358
    [No Abstract]   [Full Text] [Related]  

  • 39. [General principles of dose-effect relationship].
    Borg C; Trillet-Lenoir V
    Bull Cancer; 2001 Sep; 88(9):833-4. PubMed ID: 11604354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mathematical modeling of cancer progression and response to chemotherapy.
    Sanga S; Sinek JP; Frieboes HB; Ferrari M; Fruehauf JP; Cristini V
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1361-76. PubMed ID: 17069522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.